Development of Pharmacovigilance System in India and Paradigm of
Pharmacovigilance Research: An Overview

Preeti      Singh; Yogesh      Vaishnav; Shekhar      Verma
Abstract

The drugs are projected to cure, prevent and treat diseases; however, there are also chances of mild or severe adverse drug reactions (ADRs) in the patients. Pharmacovigilance (PV) enhances the approach to safe medicines and healthcare, but integration into public healthcare remains a challenge in many countries. The Pharmacovigilance Programme of India (PvPI) is a nationwide programme launched by the Ministry of Health and Family Welfare (MoHFW), Government of India, on 14 July 2010. It is currently run by the Indian Pharmacopoeia Commission (IPC). Presently, 567 ADR Monitoring Centres (AMC) are functioning under PvPI across India. The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services (DGHS), and the Ministry of Health, Family & Welfare (MoHFW) Government of India is the National Regulatory Authority (NRA) of India. This review aims to trace the development of PV in India and its status among the top ADR reporting countries, with a focus on the current status of the studied ADR in different regions in India. Among the top 20 countries enthusiastic about sending ICSR per million population between 2015 and 2020, India shares 2% of the total ICSRs in VigiBase. India is now being recognized as a hub of global clinical trials and clinical research studies. Hence, it is the need of the hour in India to have a dynamic PV network system with an efficient and prudent operation method. Nevertheless, in India, PV programs are at an early stage on par with other countries, and only because of underreporting of ADRs. However, in the future, PvPI may appear as a big dashboard for ADR reporting culture in India as it continuously works hard to improve patients and drug safety.
Keywords: Pharmacovigilance, Adverse drug reaction (ADR), Pharmacovigilance Programme of India (PvPI), History of pharmacovigilance, Regulation of pharmacovigilance, Drug safety, Regulatory System in India.
Graphical Abstract

[1]
WHO. The safety of medicines in public health programmes: Pharmacovigilance an essential tool. Geneva: World Health Organization 2006.

[2]
Agrawal M, Singh P, Hishikar R, Joshi U, Maheshwari B, Halwai A. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year. Indian J Pharmacol  2017; 49(6): 432-7.
 [http://dx.doi.org/10.4103/ijp.IJP_781_16] [PMID: 29674797]

[3]
Trifirò G, Crisafulli S. A new era of pharmacovigilance: Future challenges and opportunities. Front Drug Safe Regul  2022; 2: 866898.
 [http://dx.doi.org/10.3389/fdsfr.2022.866898]

[4]
Dhingra-Kumar N, Brusaferro S, Arnoldo L. Patient safety in the world. In: Textbook of Patient Safety and Clinical Risk Management.  Cham: Springer 2021; pp. 93-8.
 [http://dx.doi.org/10.1007/978-3-030-59403-9_8]

[5]
Beninger P. Pharmacovigilance: An Overview. Clin Ther  2018; 40(12): 1991-2004.
 [http://dx.doi.org/10.1016/j.clinthera.2018.07.012] [PMID: 30126707]

[6]
Panda S. Influence of research and development (R&D) cost on profitability: A study of indian pharmaceutical sector. Splint Int J Prof  2017; 4(1): 60-6.

[7]
Vennu V, Saini PP. India’s clinical trial regulatory changes, Indian researchers? Awareness of recently changed regulations, and the impact of the new drugs and clinical trial rules: A review. Indian J Pharm Sci  2020; 82(5): 726-40.

[8]
Kalaiselvan V, Srivastava S, Singh A, Gupta SK. Pharmacovigilance in India: Present scenario and future challenges. Drug Saf  2019; 42(3): 339-46.
 [http://dx.doi.org/10.1007/s40264-018-0730-7] [PMID: 30269244]

[9]
Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol  2007; 39(3): 124-8.
 [http://dx.doi.org/10.4103/0253-7613.33431]

[10]
Dhikari P, Paul S. History of indian traditional medicine: a medical inheritance. Asian J Pharmaceut Clini Res  2018; 11(1): 421.

[11]
Jeffery R. Allopathic medicine in India: A case of deprofessionalization? Soc Sci Med  1977; 11(10): 561-73.
 [http://dx.doi.org/10.1016/0037-7856(77)90174-3] [PMID: 594766]

[12]
Basu M. History of Indigenous Pharmaceutical Companies in Colonial Calcutta (1855–1947).  (1st ed.). Routledge: NY 2021; p. 272.

[13]
Neogi C, Kamiike A, Sato T. Identification of factors behind performance of pharmaceutical industries in India. Discussion paper, Research Institute for Economics & Business Administration, Kobe University. 2012. Available from: https://ideas.repec.org/p/kob/dpaper/dp2012-23.html

[14]
WHO. The world medicines.  2004. Available from: http://apps.who.int/medicinedocs/es/d/Js6160e/

[15]
Greene W. The emergence of India’s pharmaceutical industry and implications for the US generic drug market. DC: US International Trade Commission, Office of Economics Washington 2007. Available from: EC200705A.pdf (usitc.gov)

[16]
Racherla US. Historical evolution of India’s patent regime and its impact on innovation in the Indian pharmaceutical industry. In: Innovation, Economic Development, and Intellectual Property in India and China.  Singapore: Springer 2019; pp. 271-98.
 [http://dx.doi.org/10.1007/978-981-13-8102-7_12]

[17]
Malerba F, Orsenigo L. The evolution of the pharmaceutical industry. Bus Hist  2015; 57(5): 664-87.
 [http://dx.doi.org/10.1080/00076791.2014.975119]

[18]
He J. Indian patent law and its impact on the pharmaceutical industry: What can China learn from India? In: Innovation, economic development, and intellectual property in India and China.  Singapore: Springer 2019; pp. 251-69.

[19]
Case Reads. Coffee Industry in India: Growth, Challenges, and the Future. 2020. Available from: https://casereads.com/coffee-industry-in-india-growth-analysis-and-the-future/

[20]
FICCI. Indian Pharmaceutical Industry 2021: Future is now. EY. 2021. Available from: https://assets.ey.com

[21]
Sarwal R, Prasad U, Gopal KM, et al. Investment opportunities in India’s healthcare sector.  Niti Ayog 2021; pp. 1-44.
 [http://dx.doi.org/10.31219/osf.io/rtup2]

[22]
Lodha S, Patel H, Joshi S, Kalyankar G, Mishra A. Chapter 6 -Regulatory requirements of regulated market. In: Ali J, Ed. Baboota SBTRA in the PI.  Academic Press: Massachusetts 2022; pp. 113-61.

[23]
Chowdhury N, Joshi P, Patnaik A, Saraswathy B. Administrative structure and functions of drug regulatory authorities in India. ICRIER Working Paper 309. 2015. Available from: https://lccn.loc.gov/2018305081

[24]
National institute of biologicals. National drug survey, India 2014-2016. 2014. Available from: https://mohfw.gov.in/sites/default/files/Chapter1background.pdf

[25]
Evolution of Indian pharma regulatory framework - BPD  Available from: http://www.expressbpd.com/pharma/cover-story/evolution-of-indian-pharma-regulatory-framework/388992/

[26]
Imran M, Najmi A, Rashid M, Tabrez S, Shah M. Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to go. J Pharm Bioallied Sci  2013; 5(1): 2-9.
 [http://dx.doi.org/10.4103/0975-7406.106553] [PMID: 23559817]

[27]
Seth SD, Singh S, Maulik M. Indian regulatory framework. In: Global Clinical Trials.  Amsterdam: Elsevier 2011; pp. 89-118.
 [http://dx.doi.org/10.1016/B978-0-12-381537-8.10006-8]

[28]
Joshi P. Administrative structure and functions of drug regulatory authorities in India, Indian council for research on international economic relations. 2015. Available from: https://policycommons.net/artifacts/1623845/administrative-structure-and-functions-of-drug-regulatory-authorities-in-india/2313769/ (Accessed on: 25 Jul 2022).

[29]
He Y, Toldo L, Burns G, Tao C, Abernethy DR. A 2012 Workshop: Vaccine and drug Ontology in the study of mechanism and effect (VDOSME 2012). J Biomed Semantics  2012; 3(1): 12.
 [http://dx.doi.org/10.1186/2041-1480-3-12] [PMID: 23249650]

[30]
WHO. Medicines regulation: Regulatory systems in India. WHO Drug Inf  2017; 31(3): 387-401.

[31]
Paudyal B, Thapa A, Sigdel KR, Adhikari S, Basnyat B. Adverse events with ayurvedic medicines- possible adulteration and some inherent toxicities. Wellcome Open Res.   2019; 4: p. 23.
 [http://dx.doi.org/10.12688/wellcomeopenres.15096.3]

[32]
Thomas KB. Chloroform: Commissions and Omissions. Proc R Soc Med  1974; 67(8): 723-30.
 [http://dx.doi.org/10.1177/003591577406700816] [PMID: 4609043]

[33]
Eastes G. Relative safety of anaesthetics. Lancet  1890; 135(3476): 823-4.
 [http://dx.doi.org/10.1016/S0140-6736(02)18294-8]

[34]
Analysis and report on original documentary evidence concerning the use of opium in India: IV. Mode of use.—quantities taken.—the price of the drug. Br Med J  1893; 2(1721): 1399-400.

[35]
Chopra RN, Brevet-Colonel , Chopra GS. The present position of hemp-drug addiction in India. Addiction  1940; 38(2): 71-4.
 [http://dx.doi.org/10.1111/j.1360-0443.1940.tb05405.x]

[36]
Chopra RN, Chopra GS, Chopra IC. Cannatis sativa in relation to mental diseases and crime in India. Indian J Med Res  1942; 30(1): 155-71.

[37]
Deshmukh PL. Intravenous iron therapy with saccharated iron oxide. Ind Med Gaz  1952; 87(7): 287-92.
 [PMID: 12990194]

[38]
Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ  1968; 38(2): 159-88.
 [PMID: 5302296]

[39]
Miller AB, Nunn AJ, Robinson DK, Fox W, Somasundaram PR, Tall R. A second international cooperative investigation into thioacetazone side effects: 2. Frequency and geographical distribution of side effects. Bull World Health Organ  1972; 47(2): 211-27.
 [PMID: 4118761]

[40]
Tejuja S, Choudhury SD, Saxena NC, Malhotra U, Bhinder G. Clinical experience in India with a once-a-month oral contraceptive pill: Quingestanol and quinestrol. Contraception  1974; 10(4): 375-83.
 [http://dx.doi.org/10.1016/0010-7824(74)90037-7] [PMID: 4448057]

[41]
Mutalik GS, Gulati RB, Iqbal AK. A Field Trial with Bitoscanate in India. In: Jucker E, Ed. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques.  Birkhäuser Basel 1975; 19: pp. 81-5.
 [http://dx.doi.org/10.1007/978-3-0348-7090-0_11]

[42]
Vakil BJ, Kulkarni RD, Chabria NL, Chadha DR, Deshpande VA. Intense surveillance of adverse drug reactions. An analysis of 338 patients. J Clin Pharmacol  1975; 15(5-6): 435-41.
 [http://dx.doi.org/10.1002/j.1552-4604.1975.tb02365.x] [PMID: 1133220]

[43]
Pispati PK, Paul AD, Shet UK. Monitored release trials-A case study with IBuprofen. Ind J Pharmac  1980; 2(3): 173-80.

[44]
Proceedings of the 7th International Congress of Pharmacology, Paris 1978.
 [http://dx.doi.org/10.1016/B978-0-08-023196-9.50027-5]

[45]
Doval DC, Nath C, Gulati A, Agarwal SS, Bhargava KP. Adverse drug reactions in hospitalized patients. Indian J Med Res  1983; 77: 895-901.
 [PMID: 6605918]

[46]
Shah LP, Ayyar KS, Agarawal BR, et al. Drug surveillance programme in psychiatry - adverse durg reactions. Indian J Psychiatry  1983; 25(3): 229-34.
 [PMID: 21847294]

[47]
Shankar PR. Essential medicines and health products information portal. J Pharmacol Pharmacother  2014; 5(1): 74-5.
 [http://dx.doi.org/10.4103/0976-500X.124434] [PMID: 24554918]

[48]
Kulkarni RD. Reporting systems for rare side effects of non-narcotic analgesics in India. Problems and opportunities. Med Toxicol  1986; 1(S1): 110-3.
 [PMID: 3821424]

[49]
Pradhan SC, Shewade DG, Shashindran CH, Bapna JS. Drug utilization studies. Natl Med J India  1988; 1(4): 185-9.

[50]
Prakash J, Sachdeva R, Shrivastava T, Jayachandran CV, Sahu A. Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India. Indian J Pharmacol  2021; 53(2): 143-52.
 [http://dx.doi.org/10.4103/ijp.ijp_901_20] [PMID: 34100398]

[51]
TFDA. WHO collaborative procedure  Available from: https://www.tfda.go.tz/pages/who-collaborative-procedure

[52]
Suke SG, Kosta P, Negi H. Role of pharmacovigilance in India: An overview. Online J Public Health Inform  2015; 7(2): e223.

[53]
Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO’s minimum requirements. Int J Heal policy Manag  2015; 4(5): 295-305.

[54]
Gupta YK. Pharmacovigilance programme for India.  2010; pp. 2010-1.

[55]
Kumar A. Past, present and future of pharmacovigilance in India. Sys Rev Pharm  2011; 2(1): 55-8.
 [http://dx.doi.org/10.4103/0975-8453.83440]

[56]
WHO. Safety of medicines: Pharmacovigilance programme of India. WHO Drug Inf  2018; 32(1): 10-7.

[57]
Biswas P. Pharmacovigilance in Asia. J Pharmacol Pharmacother  2013; 4(S1): S7-S19.
 [http://dx.doi.org/10.4103/0976-500X.120941] [PMID: 24347987]

[58]
Bavdekar SB, Karande S. National pharmacovigilance program. Indian Pediatr  2006; 43(1): 27-32.
 [PMID: 16465003]

[59]
Current population of India. 2018. Available from: http://countrymeters.info/en/India

[60]
Lihite RJ, Lahkar M. An update on the pharmacovigilance programme of India. Front Pharmacol  2015; 6: 194.
 [http://dx.doi.org/10.3389/fphar.2015.00194] [PMID: 26441651]

[61]
List of ADR monitoring centres under pharmacovigilance programme of India.  Available from: https://www.ipc.gov.in/mandates/pvpi/pvpi-updates.html

[62]
Vivekanandan K, Prakash J, Singh G. Pharmacovigilance programme of India. Arch Pharm Pract  2012; 3(3): 229-32.
 [http://dx.doi.org/10.4103/2045-080X.116605]

[63]
Commission IP, Welfare F. Guidance document for spontaneous adverse drug reaction reporting Indian pharmacopoeia commission national coordination centre -Pharmacovigilance programme of India ministry of health & family welfare governemnt of India.  Available from: https://who-umc.org/media/1075/india.pdf

[64]
Kalaiselvan V, Kumar R, Singh GN. Indian Pharmacopoeia commission’s partners for promoting public health. Adv Pharmacoepidemiol Drug Saf  2015; 4(181): 1052-2167.

[65]
Gough J, Nettleton D. Guidance for industry. In: Managing the Documentation Maze.  John Wiley & Sons 2010; pp. 431-50.
 [http://dx.doi.org/10.1002/9780470597507.app2]

[66]
Thota P, Thota A, Medhi B, et al. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India. Perspect Clin Res  2018; 9(1): 51-5.
 [http://dx.doi.org/10.4103/picr.PICR_29_17] [PMID: 29430420]

[67]
Tandon V, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India. Indian J Pharmacol  2015; 47(1): 65-71.
 [http://dx.doi.org/10.4103/0253-7613.150344] [PMID: 25821314]

[68]
CIOMS Cumulative Pharmacovigilance Glossary 2021. Available from: https://cioms.ch/wp-content/uploads/2021/03/CIOMS-Cumulative-PV-Glossary-v1.0.pdf

[69]
Thota P, Agrawal V, Shrivastava TP, Adusumilli PK, Vivekanandan K, Bhushan S. Pivotal role of Pharmacovigilance Programme of India in containment of antimicrobial resistance in India. Perspect Clin Res  2019; 10(3): 140-4.
 [http://dx.doi.org/10.4103/picr.PICR_29_18] [PMID: 31404182]

[70]
Medical Device Rule gsr78E(1).pdf  (globi-reg.com)

[71]
Ministry of Health and Family Welfare India. New drugs and clinical trials rules 2019. The Gazaette of India 2019; 1940(GSR 227): 147-264. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NDI2MQ==

[72]
Suvarna V. Phase IV of drug development. Perspect Clin Res  2010; 1(2): 57-60. Available from: https://pubmed.ncbi.nlm.nih.gov/21829783
 [PMID: 21829783]

[73]
Universal Immunisation Programme. Surveillance A, Aefi T Revised AEFI Guidelines: Executive Summary 2015. Available from: https://main.mohfw.gov.in/sites/default/files/Revised%20AEFI%20Guidelines%20Execute%20Summary.pdf

[74]
PvPI performance report.  Available from: https://www.ipc.gov.in/mandates/pvpi/pvpi-updates/8-category-en/646-annual-performance-report.html

[75]
Uppsala Monitoring Centre Annual. Eur Sp Agency, Special Publ ESA SP. 2020. Available from: https://annualreport.who-umc.org/

[76]
Sundaran S, Udayan A, Hareendranath K, et al. Study on the classification, causality, preventability and severity of adverse drug reaction using spontaneous reporting system in hospitalized patients. Pharmacy  2018; 6(4): 108.
 [http://dx.doi.org/10.3390/pharmacy6040108] [PMID: 30274320]

[77]
Vinutha S, Kamala K, Suresh N. A study of patterns of adverse drug reactions in a tertiary care hospital of Andhra Pradesh, India. Int J Basic Clin Pharmacol  2019; 8(5): 860-4.
 [http://dx.doi.org/10.18203/2319-2003.ijbcp20191542]

[78]
Singh A, Dwivedi S. Study of adverse drug reactions in patients with diabetes attending a tertiary care hospital in New Delhi, India. Indian J Med Res  2017; 145(2): 247-9.
 [PMID: 28639602]

[79]
Lihite RJ, Lahkar M, Das S, et al. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alex J Med  2017; 53(2): 151-6.
 [http://dx.doi.org/10.1016/j.ajme.2016.05.007]

[80]
Dela A, Tank NK, Singh A, Piparva K. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. Lung India  2017; 34(6): 522-6.
 [http://dx.doi.org/10.4103/0970-2113.217569] [PMID: 29098997]

[81]
Bansod KA, Bashir MSM, Ingle SS. Adverse drug reaction profile in Amravati region of India: A pharmacovigilance study. J Pharm Bioallied Sci  2020; 12(2): 155-62.

[82]
Ihtisham K, Ramanujam B, Srivastava S, et al. Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. Seizure  2019; 66: 99-103.
 [http://dx.doi.org/10.1016/j.seizure.2019.02.011] [PMID: 30826555]

[83]
Kumar S, Sarangi SC, Tripathi M, Gupta YK. Evaluation of adverse drug reaction profile of antiepileptic drugs in persons with epilepsy: A cross-sectional study. Epilepsy Behav  2020; 105: 106947.
 [http://dx.doi.org/10.1016/j.yebeh.2020.106947] [PMID: 32109858]

[84]
CR J. A study to analyze the pattern, causality, severity, predictability and preventability of adverse drug reactions among patients attending department of obstetrics and gynecology at a tertiary care hospital. J ICT Res Appl  2019; 9(2): 172-7.

[85]
Jha N, Alexander E, Kanish B, Badyal D. A study of cutaneous adverse drug reactions in a tertiary care center in Punjab. Indian Dermatol Online J  2018; 9(5): 299-303.
 [http://dx.doi.org/10.4103/idoj.IDOJ_81_18] [PMID: 30258795]

[86]
Modi A, Desai M, Shah S, Shah B. Analysis of cutaneous adverse drug reactions reported at the regional ADR monitoring center. Indian J Dermatol  2019; 64(3): 250.
 [http://dx.doi.org/10.4103/ijd.IJD_682_16] [PMID: 31148872]

[87]
Rajan A. A study on pattern of adverse drug reaction in an adverse drug reaction monitoring centre of a tertiary care hospital in South Kerala, India. 2019; 8(8): 113-8.

[88]
Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana SV. Analysis and reporting of adverse drug reactions at a tertiary care teaching hospital. Alex J Med  2018; 54(4): 597-603.
 [http://dx.doi.org/10.1016/j.ajme.2018.10.005]

[89]
Sharma S, Jayakumar D, Palappalli DS. Pharmacovigilance of cutaneous adverse drug reactions among patients attending dermatology department at a Tertiary Care Hospital. Indian Dermatol Online J  2019; 10(5): 547-54.
 [http://dx.doi.org/10.4103/idoj.IDOJ_419_18] [PMID: 31544074]

[90]
Singh M, Goel N, Kaur N, Sharma RK, Kumar A, Singh F, et al. A retrospective and prospective study on adverse drug reactions in a rural medical college hospital in himachal pradesh. J Adv Med Dent Sci Res  2019; 7(10): 45-50.

[91]
Misra AK, Sharma PK, Gupta A, Singh S, Dhamija P, Pareek P. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence. Indian J Pharmacol  2018; 50(5): 273-8.
 [http://dx.doi.org/10.4103/ijp.IJP_544_17] [PMID: 30636831]

[92]
Agrawal M, Singh P, Joshi U. Antimicrobials associated adverse drug reaction profiling: A four years retrospective study (Pharmacovigilance study). Alex J Med  2021; 57(1): 177-87.
 [http://dx.doi.org/10.1080/20905068.2021.1938425]

[93]
Alam MS, Pillai KK, Abdi SAH, Kapur P, Pillai PK, Nagarajan K. Adverse drug reaction monitoring during antimicrobial therapy for septicemia patients at a university hospital in New Delhi. Korean J Intern Med  2018; 33(6): 1203-9.
 [http://dx.doi.org/10.3904/kjim.2016.001] [PMID: 28874042]

[94]
Jhaj R, Asati DP, Chaudhary D, Sadasivam B. Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough. Indian J Pharmacol  2021; 53(5): 371-6.
 [PMID: 34854405]

[95]
Swathi VS, Saroha S, Prakash J, Bhushan S. Retrospective pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease. Indian J Pharmacol  2021; 53(3): 192-7.
 [PMID: 34169903]

[96]
Kalaiselvan V, Thota P, Singh G. Pharmacovigilance programme of India: Recent developments and future perspectives. Indian J Pharmacol  2016; 48(6): 624-8.
 [http://dx.doi.org/10.4103/0253-7613.194855] [PMID: 28066097]

[97]
Indian Pharmacopoeia Commission. Pharmacovigilance programme of India. News letter 2021; 11(37): 1-26. Available from: https://www.ipc.gov.in/images/PvPI_Newsletter_37_1.pdf

[98]
Indian Pharmacopoeia Commission. Pharmacovigilance programme of India. Annual Performance Report 2017-2018.  Available from: https://www.ipc.gov.in/mandates/pvpi/pvpi-updates/8-category-en/646-annual-performance-report.html

[99]
Indian Pharmacopoeia Commission. Pharmacovigilance programme of India Annual Performance Report 2020-2021  Available from: https://www.ipc.gov.in/mandates/pvpi/pvpi-updates/8-category-en/646-annual-performance-report.html

[100]
Pavithra MS, Vijendra R, Xaviar S. A questionnaire based cross-sectional study to assess knowledge, attitude and practice of pharmacovigilance and adverse drug reaction reporting among postgraduate medical students in a tertiary care teaching hospital of South India. Res J Pharm Technol  2022; 15(6): 2391-4.

[101]
Sandberg A, Salminen V, Heinonen S, Sivén M. Under-reporting of adverse drug reactions in Finland and healthcare professionals’ perspectives on how to improve reporting. In: Healthcare MDPI.   2022; p. 1015.

[102]
Dutta A, Banerjee A, Basu S, Chaudhry S. Analysis of under-reporting of adverse drug reaction: Scenario in India and neighbouring countries. IP Int J Compre Adv Pharmacol  2020; 5(3): 118-24.
 [http://dx.doi.org/10.18231/j.ijcaap.2020.025]

[103]
Varallo FR, Guimarães SOP, Abjaude SAR, Mastroianni PC. Causes for the underreporting of adverse drug events by health professionals: A systematic review. Rev Esc Enferm USP  2014; 48(4): 739-47.
 [http://dx.doi.org/10.1590/S0080-623420140000400023] [PMID: 25338257]

[104]
Richa, Tandon VR, Sharma S, Khajuria V, Mahajan V, Gillani Z. Adverse drug reactions profile of antimicrobials: A 3-year experience, from a tertiary care teaching hospital of India. Indian J Med Microbiol  2015; 33(3): 393-400.
 [http://dx.doi.org/10.4103/0255-0857.158564] [PMID: 26068342]

[105]
Thota P, Thota A, Sarma P, Medhi B. An overview of spontaneous reporting, targeted spontaneous reporting and cohort event monitoring-pharmacovigilance methods: Myths and facts. J Pharm Pract Comm Med  2022; 8(1): 08-13.
 [http://dx.doi.org/10.5530/jppcm.2022.1.3]

[106]
Khattri S, Balamuralidhara V, Pramod KTM, Valluru R, Venkatesh MP. Pharmacovigilance regulations in India: A step forward. Clin Res Regul Aff  2012; 29(2): 41-5.
 [http://dx.doi.org/10.3109/10601333.2012.692688]
Cite As
Current Drug Safety

Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview

Abstract

Graphical Abstract
